Preoperative Sildenafil Administration for Hepatectomy

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Hepatectomy is an important treatment for liver diseases, and bleeding is one of the most common complications during dissection of the liver parenchyma. The Control Low Central Venous Pressure (CLCVP) technique is currently one of the most important techniques to control intraoperative bleeding. It mainly consists of fluid restriction, position adjustment, and the use of vasodilators. However, these measures focus on decreasing CVP by reducing the volume of return blood, and less attention is paid to factors such as pulmonary vascular resistance and cardiac function. Sildenafil, known as Viagra, is currently used to treat erectile dysfunction and pulmonary hypertension in men. Its action inhibits phosphodiesterase-5 (PDE-5) and increases cGMP levels, leading to smooth muscle relaxation and vasodilation. Its pharmacological properties provide potential value for the treatment of many diseases. However, few studies have been conducted both domestically and internationally on the use of sildenafil citrate in liver resection related to CLCVP. This study aims to investigate the influence of preoperative oral administration of Sildenafil Citrate combined with IPM on IBL and surgical results during open or laparoscopic hepatectomy, as well as its safety and feasibility. It is expected to provide an innovative management optimization plan for reducing the bleeding in hepatectomy and to provide empirical support for the potential value of Sildenafil Citrate or Sildenafil-like drugs in improving the safety and quality of perioperative hepatectomy patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: t
View:

• Patients undergoing hepatic resection

• age from 18-85 years

• Child-Pugh ≤B

• ASA II-III

• willing to join the trial.

Locations
Other Locations
China
Zhiming Zhang
RECRUITING
Chenzhou
Contact Information
Primary
Qisheng Z Chen
cqs19990715@163.com
+8618711451175
Backup
pan wang
Showmeyoumoney@163.com
+8618075506668
Time Frame
Start Date: 2024-02-01
Estimated Completion Date: 2024-12-30
Participants
Target number of participants: 16
Treatments
Other: calcium tablet
calcium tablet
Sponsors
Leads: First People's Hospital of Chenzhou

This content was sourced from clinicaltrials.gov

Similar Clinical Trials